Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients by Bottini, A et al.
Randomized Phase II Trial of Letrozole and Letrozole Plus
Low-Dose Metronomic Oral Cyclophosphamide As Primary
Systemic Treatment in Elderly Breast Cancer Patients
Alberto Bottini, Daniele Generali, Maria Pia Brizzi, Stephen B. Fox, Alessandra Bersiga, Simone Bonardi,
Giovanni Allevi, Sergio Aguggini, Giuliana Bodini, Manuela Milani, Rossana Dionisio, Claudio Bernardi,
Arianna Montruccoli, Paolo Bruzzi, Adrian L. Harris, Luigi Dogliotti, and Alfredo Berruti
A B S T R A C T
Purpose
To investigate the activity of letrozole plus/minus oral metronomic cyclophophamide as primary
systemic treatment (PST) in elderly breast cancer patients.
Methods
One hundred fourteen consecutive elderly women with T2-4 N0-1 and estrogen receptor–
positive breast cancer were randomly assigned to primary letrozole therapy (2.5 mg daily for
6 months) or a combination of letrozole plus oral cyclophosphamide (50 mg/daily for 6 months)
in an open-labeled, randomized phase II trial. Tumor response was assessed clinically, and
tumor Ki67 index and vascular endothelial growth factor (VEGF) -A levels were measured
before and after treatment.
Results
Overall response rate was 71.9% (95% CI, 60.0 to 83.8) in the 57 patients randomly assigned to
receive primary letrozole and 87.7% (95% CI, 78.6 to 96.2) in the 57 patients randomly assigned
to receive letrozole plus cyclophosphamide. The difference in activity between treatment arms
was predominantly confined to patients with ductal histology. There was a significantly greater
suppression of Ki67 and VEGF-A expression in the letrozole/cyclophosphamide-treated group than
in the letrozole-treated group, leading to lower Ki67 and VEGF expression at post-treatment
residual histology (P  .03 and P  .002, respectively).
Conclusion
Both letrozole and letrozole plus cyclophosphamide treatments appeared active as PST in elderly
breast cancer patients. Metronomic scheduling of cyclophosphamide may have an antiangioge-
netic effect and the combination of letrozole plus cyclophosphamide warrants testing in a
randomized phase III trial.
J Clin Oncol 24:3623-3628. © 2006 by American Society of Clinical Oncology
INTRODUCTION
Primary systemic antineoplastic therapy (PST) is a
means of testing in vivo the sensitivity of breast can-
cer to novel therapeutic approaches.1 In hormone
receptor–positive postmenopausal women, endo-
crine therapy can significantly reduce the tumor vol-
ume over a 3- to 4-month treatment.2,3
Aromatase inhibitors have been shown to
be superior to tamoxifen and are being tested
extensively as PST in place of tamoxifen.2,3 Re-
sponse rates of between 40% and 60% have
been reported with aromatase inhibitors in ran-
domized clinical trials.2,3 Although it is un-
known whether clinical response correlates
with long-term outcome, very few patients ex-
perience progressive disease. These encourag-
ing results may be improved by combining
treatments showing synergistic activity as well as drugs
able to circumvent endocrine resistance.
Metronomic chemotherapy is the frequent ad-
ministration of cytotoxic drugs at doses that are low
enough to avoid dose-limiting adverse effects, which
would otherwise require rest periods.4 This treat-
ment modality may target tumor cells indirectly
via inhibiting angiogenesis and vasculogenesis by
continuously exposing the more slowly proliferating
tumor endothelial cells to cytotoxic therapy.5-8 Low-
dose metronomic chemotherapy may offer several
advantages, including low toxicity and treatment
response irrespective of the resistance profile of the
tumor cell population.9-13
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Chemotherapy efficacy is dependent mainly on proliferative
activity, whereas endocrine therapies are cytostatic, so that an
antagonistic interaction between the two treatment modalities is
expected when they are administered concomitantly.14 The results
of a large randomized clinical trial published recently are in line
with these assumptions.15
Because the target of the metronomic chemotherapy is not the
proliferating cancer cells, this treatment modality could potentiate the
efficacy of endocrine therapy.
Because of the increased expression of estrogen receptor (ER),
the sensitivity of breast cancer to endocrine therapy increases with the
age of the patient.16 Endocrine therapy is therefore the standard treat-
ment for older women both in early and metastatic setting. Because
the low toxicity profile of chemotherapy administered on a metro-
nomic schedule makes this modality feasible in the elderly patient
population, a randomized phase II trial of letrozole (LET) therapy
versus letrozole plus metronomic cyclophosphamide (LET-CYC)
as PST in elderly breast cancer patients was conducted at the Breast
Unit of Cremona (Italy). The primary aim was to evaluate the
activity of the two treatments, with secondary aims to assess the
effect of metronomic scheduling on tumor cell proliferative and
angiogenetic activity.
METHODS
Patients
Elderly women (age 70 years) or women between 65 and 70 years of
age unfit for chemotherapy with clinical T2-4 N0-1 and ER-positive (ER)
and/or progesterone receptor–positive (PgR) breast cancer were eligible.
They had an Eastern Cooperative Oncology Group performance status of 2
or lower, adequate bone marrow reserve (WBC count, 3.5 109/L; plate-
lets,  100  109/L; hemoglobin,  10g/dL), hepatic function (AST/ALT
bilirubin and alkaline phosphatase levels 1.25 the upper limit of normal
value), and renal function (serum creatinine  1.25 the upper limit of
normal value). Patients with nonmalignant disease that precluded them from
receiving study therapy and patients with second primary malignancies were
not eligible. The study was approved by the local ethical committee. Written
informed consent was obtained from all patients before randomization.
Treatment Schedule
Patients were randomized to receive LET alone, or LET-CYC on a 1:1
ratio. Treatment was started within 1 day of diagnosis. Patients in the LET arm
received letrozole (Femara, Novartis, Milan, Italy) 2.5 mg (1 tablet) daily;
patients on LET-CYC arm received letrozole and cyclophosphamide (En-
doxan, Baxter, Italy) 50 mg (one tablet) daily. These drugs were administered
continuously for 6 months until definitive surgery.
Treatment Evaluation and Adverse Effects
On presentation, an incision biopsy was performed on each patient and
a small tissue sample (0.5 to 0.8 cm) removed. Each month, the size of the
primary tumor was measured with a caliper by the same clinician. Response
was assessed according to WHO criteria17 by the measurement of the
changes in the product of the two largest diameters recorded in two
successive evaluations. Pathologic complete response (pathCR) was de-
fined as the absence of neoplastic cells in the breast and in the axillary
lymph nodes after histologic examination.
Surgery was planned after full clinical reassessment. Quadrantectomy or
radical mastectomy was performed when indicated in association with full
axillary node dissection.
Toxicity was evaluated according to WHO criteria.17 No LET reduc-
tion was planned. LET was planned to be interrupted in case of severe
adverse events.
CYC administration was delayed for the needed time in case of neutro-
phil count less than 1,500 mm3 and/or platelet count less than 100,000 mm3.
No dose reduction was adopted. In the event of grade 2 or greater nausea,
vomiting, anorexia, increase in transaminases, CYC therapy was interrupted
and postponed until symptoms were recovered. Any other adverse effects
(grade 3 toxicity) were managed with a postposition of the CYC treatment
until full recovery had occurred.
Immunohistochemistry
Immunohistochemical evaluation was performed on paraffin-
embedded tumor samples obtained at diagnosis and at definitive surgery. ER,
PgR, and Ki67 staining were done at the Pathology Unit of the Azienda
Ospedaliera Istituti Ospitalieri of Cremona (Italy), and vascular endothelial
growth factor (VEGF) staining was assessed at the John Radcliffe Hospital in
Oxford (United Kingdom). The immunohistochemical methodology is fully
described elsewhere.18-20
Random Assignment and Blinding Procedures
Random assignment was performed using permuted blocks of four
assignments in random sequence. The study was open, but the clinician who
evaluated all clinical responses (A.Bo.) and the pathologists, either in Cremona
or in Oxford, were blinded to treatment assignment.
Statistical Analysis
This randomized trial was treated as two simultaneous phase II studies.
The primary end point was the clinical response (complete response [CR]
partial response) rate of each treatment arm among all registered cases (intent-
to-treat analysis). LET-CYC was the experimental therapy arm, whereas LET
was the standard-therapy arm. On the basis of the activity of primary LET
reported in a previous randomized trial,2 the study was designed to test the null
hypothesis that the objective response rate in both arms was less than 60%.
According to Simon,21 a two-stage design was used for both treatment arms to
allow early termination of inactive arm(s). With a two-sided alpha of 0.05 and
a power of 0.90 to detect a true response probability of 80%, in the first stage, 19
patients were entered onto each arm. If in this stage, more than 12 responses to
a treatment have been recorded, the corresponding arm passed to the second
stage, with an additional 34 patients recruited. The upper limit of second-stage
rejection in each arm was 37 responses observed out of 53 patients enrolled.
To assess the presence of heterogeneity in the effect of the experimental
treatment in patient subgroups identified by various prognostic factors (T and
N stage, primary histology, tumor grade, PgR status, Ki67, and VEGF expres-
sion), a series of logistic regression models were fitted to the data with objective
response as dependent variable. The covariates included in each model were
treatment and each prognostic factor, one at a time. The presence of a modi-
fication of treatment effect in the subgroups identified by each of these factors
was assessed by including in the model the appropriate treatment/covariate
interaction term(s). The likelihood ratio test was used to evaluate the signifi-
cance of each interaction term. This procedure is equivalent to a test of the
homogeneity of the odds ratios associated with the experimental treatment in
the various strata defined by each prognostic factor. Stratum specific odds
ratios with their 95% CI are also presented.
Comparison of the distribution of discrete variables in the two treatment
arms was performed by the 2 or 2 for trend when appropriate. For contin-
uous variables, comparisons used the Mann-Whitney U test for nonparamet-
ric data. All tests were two sided; P  .05 was considered as statistically
significant. Statistical analysis was performed on an IBM-compatible per-
sonal computer using Statistica software (Statsoft, Tulsa, OK) for Win-
dows (Microsoft, Redmond, WA) software.
RESULTS
From November 2000 to January 2004, 114 patients were enrolled, 57
were randomly assigned to receive LET alone and 57 LET-CYC.
Patients’ characteristics are outlined in Table 1. As shown in Figure 1,
two patients were ineligible but were included in the intent-to-treat
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analysis. One hundred four patients (52 in LET and 52 in LET-CYC
arm) completed the planned 6 months of therapy, nine were evaluated
for response earlier, and one patient was not assessable. The frequency
of early treatment discontinuation, resulting from disease progression
and patient refusal, did not differ between the treatment arms.
Treatment Toxicity
The most frequent relevant adverse events recorded in both arms
were cardiac events and bone-related events. Three patients (two
randomly assigned to LET and one to LET-CYC) experienced fatal
heart failure after 11, 7, and 6 months from random assignment,
respectively. One LET-CYC patient had reversible atrial flutter after 8
months from random assignment. Among bone-related events, three
patients (two LET-CYC and one LET) suffered skeletal fractures lead-
ing to death in one patient. Three patients (two LET and one LET-
CYC) suffered from osteoporotic bone pain. Other adverse events
included deep venous thrombosis (one LET-CYC patient), mild
(grade 1 and 2) asthenia (two LET patients), and mental impairment
(one LET-CYC patient). CYC-related toxicities were grade 4 throm-
bocytopenia (one patient), grade 2 WBC (two patients), grade 3 cys-
titis (one patient); grade 2 cystitis (one patient). No patients
interrupted nor delayed LET treatment. One patient interrupted
CYC administration after 4 months of treatment because of grade
3 cystitis, and one patient delayed CYC for 2 weeks because of grade
4 thrombocytopenia.
Treatment Response
Overall response rate was 50 of 57 (87.7%; 95% CI, 78.6 to
96.2) in the LET-CYC arm and 41 of 57 (71.9%; 95% CI, 60.8 to
83.8), in the LET arm. Complete clinical response, pathCR, and in
situ residual carcinoma were similarly distributed between treat-
ment arms (Table 2).
The proportion of responders in the two treatment arms in
patient subsets stratified according to baseline clinical and biologic
prognostic parameters is shown in Table 3, together with the odds
Table 1. Patient Characteristics
LET LET-CYC
No. % No. %
No. of patients 57 57
Age, years
Median 79 75
Range 64-89 62-94
PgR status
Positive 36 64.3 33 57.9
Negative 20 35.7 24 42.1
Not assessable 1 —
TNM
T2 42 73.7 44 77.2
T3-4 15 26.3 13 22.8
N0 35 61.4 41 71.9
N1 22 38.6 16 28.1
Primary histology
Ductal carcinoma 44 77.2 47 82.5
Lobular carcinoma 13 22.8 10 17.5
Grading
2 22 38.6 22 39.3
3 35 61.4 34 60.7
Not assessable — 1
Ki67 expression, %
 10 24 42.1 19 33.3
11-29 28 49.1 30 52.6
 30 5 8.8 8 14.1
VEGF expression
1 12 23.1 11 20.8
2 23 44.2 20 37.7
3 17 32.7 22 41.5
Not assessable 5 4
Abbreviations: LET, letrozole; CYC, cyclophosphamide; VEGF, vascular endo-
thelial growth factor. Fig 1. CONSORT diagram. VEGF, vascular endothelial growth factor.
Table 2. Distribution of Disease Response According to Treatment Arm
LET LET-CYC
No. % No. %
Not assessable 1 1.7 —
Progressive disease 3 5.3 3 5.3
Stable disease 12 21.0 4 7.1
Partial response 18 31.6 25 43.8
Complete response 23 40.3 25 43.8
Overall response 41 71.9 50 87.7
95% CI 60.8% to 83.8% 78.6% to 96.2%
Pathologic response 2 3.5 2 3.5
Residual in situ carcinoma 1 1.8 1 1.8
Abbreviations: LET, letrozole; CYC, cyclophosphamide.
LET-CYC in Elderly Breast Cancer Patients
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ratio (OR) of response (LET-CYC v LET) in the various strata and in
the overall study population. Overall, the combined treatment was
associated with a 2.79 (95% CI, 1.05 to 7.42) increased odds of re-
sponse when compared with LET alone (P  .04). No significant
heterogeneity in the effect of LET-CYC as compared with LET was
observed when analyses were stratified according to T, N, grading, PgR
status, Ki67, and VEGF expression. However, a statistically significant
interaction between treatment and tumor histology was observed,
indicating that the addition of CYC to LET resulted in a more marked
activity than LET in patients with ductal carcinoma (OR, 4.03; 95% CI,
1.19 to 13.67; test for interaction P .02).
Ninety-seven patients, 45 randomly assigned to the LET arm and
52 to the LET-CYC arm, underwent surgery. Seventeen patients were
not operated on because of patient refusal (15 patients) and death
(two patients). At the last follow-up (March 2005), 22 patients pro-
gressed and 11 died (median follow-up, 25 months). The proportion
of patients alive and disease free after 2 years was 83.5% and 82.0% in
the LET and LET-CYC arm, respectively. Thirteen patients were lost to
follow-up, seven in the LET and sex in FEM-CYC arm, respectively.
They were censored at the date of last follow-up examination.
Changes in Ki67 Expression
Baseline and postchemotherapy Ki67 expression in 88 matched
cases is depicted in Figure 2. At baseline, no difference in Ki67 immu-
nostaining between treatment arms was observed. Both LET and LET-
CYC treatments resulted in a significant reduction in Ki67 expression
before treatment. At postchemotherapy, residual histology Ki67 expres-
sion was lower in LET-CYC patients than in LET patients (P .03).
Changes in VEGF Expression
Table 4 displays the distribution of VEGF score between the two
arms before and after treatment in 83 matched cases. Although there
was no difference in VEGF expression at baseline, VEGF immuno-
staining was significantly lower in LET-CYC patients than in LET ones
(P  .002). In particular, 35% positive VEGF tumors at baseline
become negative at the end of treatment in LET-CYC arm as opposed
to 8% in the LET arm.
Clinical response was observed in 17 of 19 patients attaining a
complete VEGF reduction (89.5%), 33 of 40 patients with partial
VEGF reduction (82.5%) and in 17 of 24 patients with VEGF no
change or increase (70.8%; 2 P for trend .12).
DISCUSSION
Endocrine therapy is the optimal PST in elderly breast cancer patients
because of the high tumor sensitivity of these patients to endocrine ma-
nipulation and the limited compliance of most of them to chemotherapy
Table 3. Distribution of Response Rates Between the Two Treatment Arms According to Clinical and Biologic Tumor Features
LET LET-CYC
OR 95% CI P
Total
No.
No.
Responding %
Total
No.
No.
Responding %
T2 31 42 73.8 38 44 86.4 2.77 0.87 to 8.81 .99
T3-T4 10 15 66.7 12 13 92.3 2.75 0.43 to 17.49
N0 24 35 68.6 38 41 92.7 5.81 1.47 to 23.0 .07
N1 17 22 77.3 12 16 75.0 0.88 0.19 to 3.99
Ductal carcinoma 32 44 72.7 43 47 91.5 4.03 1.19 to 13.67 .02
Lobular carcinoma 9 13 69.2 7 10 70.0 1.04 0.17 to 6.23
Grading 2 17 22 77.3 19 22 86.4 1.86 0.39 to 8.99 .55
Grading 3 24 35 68.6 30 34 88.2 3.44 0.97 to 12.17
PgR 14 20 70.0 22 24 91.7 4.71 0.83 to 26.72 .46
PgR 26 36 72.2 28 33 84.8 2.15 0.65 to 7.14
Ki67  10% 20 24 83.3 16 19 84.2 1.07 0.21 to 5.47 .15
Ki67  10% 21 63.6 34 38 89.5 4.86 1.38 to 17.05
VEGF staining
1 9 12 75.0 10 11 90.9 3.33 0.29 to 38.08 .92
2 16 23 69.6 16 20 80.0 1.75 0.43 to 7.17
3 13 17 76.5 20 22 90.9 3.08 0.49 to 19.28
Overall 41 57 71.9 50 57 87.7 2.79 1.05 to 7.42 .04†
Abbreviations: LET, letrozole; CYC, cyclophosphamide; OR, odds ratio; PgR, progesterone; VEGF, vascular endothelial growth factor.
Test for heterogeneity of the ORs of response.
†Comparison of response rate in the two treatment arms.
Fig 2. Ki67 expression at baseline and post chemotherapy residual histology.
Ki67 expression at post therapy residual histology was significantly lower in
patients randomized to receive letrozole plus cyclophosphamide as opposed to
those receiving letrozole alone.
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administered at conventional doses. In this article, we explored the
activity of the combination of LET-CYC administration as PST in
elderly breast cancer patients as compared to standard LET. The re-
sponse rate of 72% in patients randomly assigned to the LET arm was
higher than the 60% obtained in a previous randomized trial with
primary LET therapy.2 The different patient population and the
longer exposure of our patients to LET (6 months v 4 months) can
account for the observed difference.
The response rate obtained in the LET-CYC arm (88%) was high.
The study design was not aimed at testing the difference in response
rates in the two treatment arms, and both passed the test of activity.
However, the comparison with the randomized control arm indicates
that the high activity of the experimental arm was not caused by a
biased sample,22 and suggests that the addition of CYC is associated
with an increase in the activity of LET in this patient population (OR,
2.79). Although these results are encouraging, they failed to be con-
firmed by pathCR, a known predictor of long-term outcome. pathCR
was observed in two patients (3.5%), one in each arm. A very low
pathCR with primary LET therapy (1.7%) was obtained in the ran-
domized trial comparing LET versus tamoxifen,2 suggesting that this
condition is not a sensitive end point for primary endocrine therapy.
The addition of metronomic CYC failed to increase the pathCR rate.
Others have also found that patients with ER tumors have a low
propensity to obtain pathCR after chemotherapy.23,24
The exploratory subgroup analyses according to baseline prog-
nostic parameters, suggest that the increased activity associated with
the addition of CYC to LET seems to be more marked in (or confined
to) patients with ductal histology.25 Even though caution should be
adopted in interpreting data coming from subgroup analyses, one
might speculate that the addition of metronomic chemotherapy in
this subset of patients could improve treatment results.
The efficacy of chemotherapy administered at conventional
doses is mainly dependent on actively proliferating cells that might be
countered by concomitant endocrine therapy that reduces tumor
proliferative activity.15 However, because the target of metronomic
chemotherapy is not the proliferative compartment,4 the coadminis-
tration of metronomic chemotherapy with endocrine therapy should
not interfere but enhance the efficacy of the combination.
In a randomized neoadjuvant trial comparing anastrozole versus
tamoxifen versus the combination of both drugs (Immediate Pre-
operative Anastrozole Tamoxifen or Combined with Tamoxifen
[IMPACT]),26 it was shown that reduction in Ki67 after anastrozole
was greater than that obtained with either tamoxifen or the combina-
tion. Mean changes in Ki67 in the IMPACT trial were reflected in
differences in disease-free survival in the Arimidex Tamoxifen and
Combination (ATAC) adjuvant trial,27 suggesting that reduction in
Ki67 after endocrine therapy is predictive of long-term outcome. In
the present study the addition of metronomic CYC to LET led to a
greater reduction in proliferative activity as assessed by changes in
percent of Ki67-positive tumor cells before and after treatment, further
supporting the potential synergy between the two treatments. The target
of metronomic therapy is the endothelial cell, but the additional effect on
Ki67 in tumor cells could have been indirect, because of effects on vessels.
The more proliferative tumors have a higher oxygen demand and may be
more sensitive to an antivascular component. It is also possible that even
this low-dose of CYC has a direct effect on tumor cell proliferation.
The antiangiogenetic effect of metronomic chemotherapy has
been evaluated rarely in the clinic. To our knowledge, this is the first
randomized PST trial evaluating the effects on VEGF directly in the
tumor. In our series, LET showed a modest reduction in VEGF expres-
sion, probably mediated by estrogen deprivation.28 The addition of
CYC resulted in a greater reduction of VEGF immunostaining than
LET alone, leading to a lower VEGF expression at post-treatment
residual disease. Probably because of the limited sample size of the
study, the relationship between disease response and changes in VEGF
immunostaining failed to attain statistical significance. It should be
noted, however, that the efficacy of an antiangiogenetic drug may not
necessarily be linked to the disease response obtained.
One mechanism by which metronomic therapy has been shown
to work is reduction of endothelial proliferation, and another through
inhibition of mobilization of bone marrow endothelial progenitor
cells, both of which are partly regulated by VEGF.29,30 Our results
suggest that inhibition of production of VEGF in the tumor may be
one mechanism by which such therapy works on both targets. Whether
thiseffectwouldoccurwithCYCalonecannotbeassessedinthis trial,and
it will be of interest to evaluate effects on other angiogenetic factors.
Nevertheless, although long-term skeletal and cardiac toxicities
of LET therapy are recognized,31 in this trial few patients experienced
heart failure and bone fractures. The age of patients experiencing these
adverse events was 79 years, close to average life expectancy, and
treatment exposure was relatively short, so that it is difficult to state
whether the events should be attributed to LET administration. The
uniform distribution of events between the treatment arms, however,
suggest that they were not influenced by concomitant CYC adminis-
tration. The adverse effects attributable to CYC were modest and
rarely dose limiting.
In conclusion, concomitant administration of metronomic CYC
and LET appears to be a feasible and active PST in elderly breast cancer
patients. These results warrant testing the combination LET-CYC
against LET in a phase III study.
Table 4. Changes in VEGF Expression Before and After Treatment According to the Randomized Treatment Arm
Before After
LET LET-CYC LET LET-CYC
No. % No. % No. % No. %
0 — — 3 7.9 16 35.5
1 8 21.0 8 17.8 20 52.6 21 46.7
2 18 47.4 17 37.8 12 31.6 8 17.8
3 12 31.6 20 44.4 3 7.9 —
NOTE. P  .002. 2 for trend. Post-treatment VEGF 2 and 3 were considered as the same group.
Abbreviations: LET, letrozole; CYC, cyclophosphamide; VEGF, vascular endothelial growth factor.
LET-CYC in Elderly Breast Cancer Patients
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